RGEN

Business Context and Reporting Period

Company: Repligen Corporation (RGEN)
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2010
Business Overview: Repligen is a biopharmaceutical company with two primary business segments: (1) a bioprocessing business manufacturing Protein A products for monoclonal antibody purification, and (2) a therapeutic development pipeline focusing on neurology, gastroenterology, and orphan diseases. The company also generates revenue through royalties from Bristol-Myers Squibb (BMS) on the drug Orencia®.

Key Financial Metrics (Fiscal Year 2010)

Note: Revenue consists of $10,305 in product revenue and $10,666 in royalty/other revenue. The company reported a net loss per share of $(0.13).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 29% to $20.97 million from $29.36 million in fiscal 2009. This was driven by a 28% drop in bioprocessing product sales due to lower customer demand in the economic environment and the absence of a one-time $5 million royalty payment from BMS recognized in the prior year.
• Profitability Shift: The company returned to a net loss of $4.06 million in 2010, compared to a net income of $5.75 million in 2009. The 2009 income was significantly bolstered by the BMS settlement payment and a $40.17 million net gain from an ImClone litigation settlement in 2008 (which impacted comparative operating expenses).
• Expense Increases: Research and development (R&D) expenses increased 11% to $14.16 million, primarily due to new programs for Spinal Muscular Atrophy (SMA) and Friedreich's Ataxia. Selling, General, and Administrative (SG&A) expenses rose 19% to $7.07 million due to increased headcount.
• Product Discontinuation: Sales of SecreFlo® were discontinued in fiscal 2009; no revenue was generated from this product in 2010.

Guidance, Outlook, and Risks

• Clinical Pipeline Status:
  • Secretin (RG1068): Phase 3 trial completed in Dec 2009. Due to analysis deficiencies, the company requested a re-analysis of images approved by the FDA/EMA. Preliminary results expected by end of fiscal 2011.
  • Uridine (RG2417): Phase 2b trial for bipolar depression is ongoing; preliminary results expected by end of fiscal 2011.
  • Friedreich's Ataxia (RG2833): IND application filed for Phase 1 study.
  • Spinal Muscular Atrophy: Preclinical evaluation of DcpS inhibitors is underway.
• Financial Outlook: Management expects R&D expenses to decrease moderately in fiscal 2011 as the secretin trial concludes, partially offset by increased spending on the SMA program. SG&A is expected to increase moderately. The company believes current cash balances are adequate for at least the next 24 months.
• Key Risks:
  • Customer Concentration: Royalty revenue from BMS represented 43% of total revenue in 2010. The largest bioprocessing customer accounted for 36% of revenue.
  • Patent Expiration: Key U.S. patents for recombinant Protein A expired in September 2009, potentially increasing competition.
  • Regulatory Uncertainty: Success depends on FDA approvals for clinical candidates, which are subject to significant risk and delay.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $59.1 million cash balance against the projected burn rate, given the company's history of operating losses and reliance on royalty income.
• BMS Royalty Dependency: Assess the sustainability of revenue streams given that nearly half of total revenue is derived from a single royalty agreement with Bristol-Myers Squibb.
• Phase 3 Re-read Results: Monitor the upcoming re-analysis results for the RG1068 (Secretin) Phase 3 trial, as this is critical for potential NDA filing and future revenue generation.
• Protein A Competition: Evaluate the impact of the September 2009 patent expiration on the pricing power and market share of the core bioprocessing business.
• Acquisition Integration: Review the performance of the BioFlash acquisition (completed Jan 2010) and the associated contingent liabilities ($560,000 recorded).